Our results showed both a nonsignificant effect of SGLT2 inhibitors on cancer mortality or progression and a nonsignificant effect of SGLT2 inhibitors on performance status, inflammatory markers, and malnutrition. The gene discussed is SLC5A2; the disease is malnutrition.